| Autor: |
Pepe M; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Piazza G. Cesare 11, Bari, Italy. drmartinopepe@libero.it., Maroun-Eid C; Hospital Universitario La Paz. Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain., Romero R; Hospital Universitario Getafe, Getafe, Madrid, Spain., Arroyo-Espliguero R; Hospital Universitario Guadalajara, Guadalajara, Spain., Fernàndez-Rozas I; Hospital Universitario Severo Ochoa, Leganés, Spain., Aparisi A; Hospital Clinico Universitario de Valladolid, Valladolid, Spain., Becerra-Muñoz VM; Unidad de Gestión Clínica Área del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Hospital Universitario Virgen de la Victoria, Universidad de Málaga (UMA), Málaga, Spain., Garcìa Aguado M; Hospital Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain., Brindicci G; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Piazza G. Cesare 11, Bari, Italy., Huang J; The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China., Alfonso-Rodríguez E; Institute of Cardiology and Cardiovascular Surgery, Havana, Cuba., Castro-Mejía AF; Hospital General del norte de Guayaquil IESS Los Ceibos, Guayaquil, Ecuador., Favretto S; Sant'Andrea Hospital, Vercelli, Italy., Cerrato E; Orbassano and Rivoli Infermi Hospital, San Luigi Gonzaga University Hospital, Rivoli (Turin), Italy., Albiol P; Hospital Clinico, INCLIVA, Valencia, Spain., Raposeiras-Roubin S; University Hospital Alvaro Cunqueiro, Vigo, Spain., Vedia O; Hospital Clinico San Carlos, Madrid, Spain., Feltes Guzmãn G; Nuestra Señora De America, Madrid, Spain., Carrero-Fernández A; Hospital Universitario Príncipe de Asturias, Madrid, Spain., Perez Cimarra C; Hospital Universitario Infanta Sofia. San Sebastian de los Reyes, Madrid, Spain., Buzón L; Hospital Universitario de Burgos, Burgos, Spain., Jativa Mendez JL; Hospital De Especialidades De Las Fuerzas Armadas N1, Quito, Ecuador., Abumayyaleh M; First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany., Corbi-Pascual M; Hospital General de Albacete, Albacete, Spain., Macaya C; Hospital Clinico San Carlos, Madrid, Spain., Estrada V; Hospital Clinico San Carlos, Madrid, Spain., Nestola PL; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Piazza G. Cesare 11, Bari, Italy., Biondi-Zoccai G; Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.; Mediterranea Cardiocentro, Napoli, Italy., Núñez-Gil IJ; Hospital Clinico San Carlos, Madrid, Spain. |
| Abstrakt: |
There is limited information on the presenting characteristics, prognosis, and therapeutic approaches of young patients hospitalized for coronavirus disease 2019 (COVID-19). We sought to investigate the baseline characteristics, in-hospital treatment, and outcomes of a wide cohort < 65 years admitted for COVID-19. Using the international multicenter HOPE-COVID-19 registry, we evaluated the baseline characteristics, clinical presentation, therapeutic approach, and prognosis of patients < 65 years discharged (deceased or alive) after hospital admission for COVID-19, also compared with the elderly counterpart. Of the included 5746 patients, 2676 were < 65 and 3070 ≥ 65 years. All risk factors and several parameters suggestive of worse clinical presentation augmented through increasing age classes. In-hospital mortality rates were 6.8% and 32.1% in the younger and older cohort, respectively (p < 0.001). Among young patients, mortality, access to ICU and treatment with IMVwere positively correlated with age. Contrariwise, over 65 years of age this trend was broken so that only the association between age and mortality was persistent, while the rates of access to ICU and IMV started to decline. Younger patients also recognized specific predictors of case fatality, such as obesity and gender. Age negatively impacts on mortality, access to ICU and treatment with IMV in patients < 65 years. In elderly patients only case fatality rate keeps augmenting in a stepwise manner through increasing age categories, while therapeutic approaches become more conservative. Besides age, obesity, gender, history of cancer, and severe dyspnea, tachypnea, chest X-ray bilateral abnormalities, abnormal level of creatinine and leucocyte among admission parameters seem to play a central role in the outcome of patients younger than 65 years. |
Full text from SpringerLink